Lcnb Corp Acquires 84 Shares of Johnson & Johnson (NYSE:JNJ)

Lcnb Corp grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,938 shares of the company’s stock after buying an additional 84 shares during the period. Johnson & Johnson accounts for 0.9% of Lcnb Corp’s investment portfolio, making the stock its 29th largest position. Lcnb Corp’s holdings in Johnson & Johnson were worth $2,363,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson during the 1st quarter worth about $31,000. Keener Financial Planning LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $40,000. WFA Asset Management Corp increased its stake in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $44,000. Finally, Disciplined Equity Management Inc. bought a new position in Johnson & Johnson in the 4th quarter worth about $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JNJ. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $160.00 to $150.00 in a research report on Tuesday. TD Cowen reduced their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Trading Down 1.0 %

NYSE JNJ traded down $1.56 on Tuesday, hitting $152.68. The company’s stock had a trading volume of 3,360,912 shares, compared to its average volume of 7,303,052. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The company’s 50-day simple moving average is $148.42 and its 200 day simple moving average is $153.24. The firm has a market cap of $367.45 billion, a P/E ratio of 9.47, a PEG ratio of 2.85 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.79% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business posted $2.80 EPS. The business’s revenue was up 4.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.25%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.